NCT00423449View on ClinicalTrials.gov

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

vorinostat

Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days

DRUG

Gemcitabine

Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle

DRUG

Platinum-based agent

Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00423449 - Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | Biotech Hunter | Biotech Hunter